Ganoderma lucidum Polysaccharide Peptide Reduce Inflammation and Oxidative Stress in Patient with Atrial Fibrillation
Abstract
BACKGROUND: Atrial fibrillation (AF) could be triggered by inflammation and oxidative stress. Ganoderma lucidum has an active substance in the form of β-glucan that can reduce inflammatory process and oxidative stress in rats. The objective of this study was to evaluate the effect of Ganoderma lucidum polysaccharide peptide (GLPP) in paroxysmal AF subjects with parameters of anti-inflammatory antioxidant, electrocardiography and health-related quality of life (HRQoL).
METHODS: A randomized closed-label clinical trial with pre- and post-test design was conducted. After AF subjects selection, the subjects were randomized, interviewed and veni-punctured to isolate blood plasma. AF Subjects were then treated with placebo or GLPP for 90 days. Post-test blood plasma was collected on the following day after the 90th day. Then anti-inflammatory and antioxidant parameters were measured. After that, echocardiographic and HRQoL assessments were performed.
RESULTS: A total of 38 subjects, 11 males and 27 females, completed the study with no significant changes in diets, physical activities, or medications. Comparing to control, the 90-days GLPP-treated subject characteristics were significant difference in systolic blood pressure, heart rate, malondialdehyde, high-sensitivity C-reactive protein, tumor necrosis factor-a, interleukin (IL)-1b, IL-6, primary (P)-wave dispersion, P-max, physical functioning, limitation to physical health, energy/fatigue, pain, and physical limitation.
CONCLUSION: GLPP has several potential effects in AF subjects, including anti-inflammatory, antioxidant, and atrial remodelling, so that HRQoL of AF subjects could be improved. Hence, GLPP could suggested as a potential supplementing agent for AF management.
KEYWORDS: atrial fibrillation, Ganoderma lucidum, inflammation, antioxidant, atrial remodelling, quality of life
Full Text:
PDFReferences
Rizal A, Yuniadi Y. Epigenetic implication in atrial fibrillation: a potential biomarker? J Lab Precis Med. 2019; 4: 33, CrossRef.
Yuniadi Y, Hanafy D, Rahardjo S, Tondas AE, Maharani E, Hermanto D, et al. 2014 Indonesian Heart Association Guidelines of Management of Atrial Fibrillation. Indones J Cardiol. 2014; 35: 102-33, CrossRef.
Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, Camm AJ, et al. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. Eur Heart J. 2013; 34: 2725-30, CrossRef.
Li N, Brundel BJJM. Inflammasomes and proteostasis novel molecular mechanisms associated with atrial fibrillation. Circ Res. 2020; 127: 73-90, CrossRef.
Sargowo D, Ovianti N, Susilowati E, Ubaidillah N, Widya Nugraha A, Vitriyaturrida, et al. The role of polysaccharide peptide of Ganoderma lucidum as a potent antioxidant against atherosclerosis in high risk and stable angina patients. Indian Heart J. 2018; 70: 608-14, CrossRef.
Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96: 1180-4, CrossRef.
Smit MD, Van Gelder IC. Upstream therapy of atrial fibrillation. Expert Rev Cardiovasc Ther. 2009; 7: 763-78, CrossRef.
Mohan S, Syam S, Abdelwahab SI, Thangavel N. An anti-inflammatory molecular mechanism of action of α-mangostin, the major xanthone from the pericarp of Garcinia mangostana: an in silico, in vitro and in vivo approach. Food Funct. 2018; 9: 3860-71, CrossRef.
Toufan M, Kazemi B, Molazadeh N. The significance of the left atrial volume index in prediction of atrial fibrillation recurrence after electrical cardioversion. J Cardiovasc Thorac Res. 2017; 9: 54-9, CrossRef.
Maesen B, Nijs J, Maessen J, Allessie M, Schotten U. Post-operative atrial fibrillation: a maze of mechanisms. Europace. 2012; 14: 159-74, CrossRef.
El Aouar LM, Meyerfreud D, Magalhães P, Rodrigues SL, Baldo MP, Brasil Y, et al. Relationship between left atrial volume and diastolic dysfunction in 500 Brazilian patients. Arq Bras Cardiol. 2013; 101: 52-8, CrossRef.
Rodiño-Janeiro BK, Paradela-Dobarro B, Castiñeiras-Landeira MI, Raposeiras-Roubín S, González-Juanatey JR, Alvarez E. Current status of NADPH oxidase research in cardiovascular pharmacology. Vasc Health Risk Manag. 2013; 9: 401-28, CrossRef.
Sener G, Toklu H, Ercan F, Erkanli G. Protective effect of beta-glucan against oxidative organ injury in a rat model of sepsis. Int Immunopharmacol. 2005; 5: 1387-96, CrossRef.
Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000; 36: 1303-9, CrossRef.
Dilaveris PE, Gialafos JE. P-wave dispersion: a novel predictor of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol. 2001; 6: 159-65, CrossRef.
Hu X, Jiang J, Ma Y, Tang A. Novel P wave indices to predict atrial fibrillation recurrence after radiofrequency ablation for paroxysmal atrial fibrillation. Med Sci Monit. 2016; 22: 2616-23, CrossRef.
Nakanishi K, Fukuda S, Yamashita H, Kosaka M, Shirai N, Tanaka A, et al. Pre-procedural serum atrial natriuretic peptide levels predict left atrial reverse remodeling after catheter ablation in patients with atrial fibrillation. JACC Clin Electrophysiol. 2016; 2: 151-8, CrossRef.
DOI: https://doi.org/10.18585/inabj.v12i4.1244
Copyright (c) 2020 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute